Literature DB >> 2987294

Pituitary-adrenal responsiveness to corticotropin-releasing hormone in patients receiving chronic, alternate day glucocorticoid therapy.

T H Schürmeyer, G C Tsokos, P C Avgerinos, J E Balow, R D'Agata, D L Loriaux, G P Chrousos.   

Abstract

We examined the responsiveness of the pituitary-adrenal axis to ovine corticotropin-releasing hormone (oCRH) in 14 women with systemic lupus erythematosus receiving chronic, alternate day glucocorticoid therapy with prednisone. Testing was done twice and in a random order (at 2000 h) on the day when the steroid was taken (12 h after the last dose) and on the day when no glucocorticoid was administered (36 h after the last dose). Plasma ACTH and cortisol responses were markedly blunted on the day of treatment and mildly blunted on the day off treatment compared to those in normal subjects. Altered metabolic clearance of exogenous oCRF was not responsible for this difference, since the plasma disappearance curves of immunoreactive oCRH were similar on both days. The degree of suppression was dependent on the dose of prednisone, and the amount of cortisol secreted during the oCRH test was directly proportional to the logarithm of the concurrent plasma ACTH level. Thus, the cortisol response to ACTH was normal in all patients. These data suggest that the blunting of responsiveness to oCRH on both days of testing represents prednisolone suppression of the corticotroph cell. Despite this, the adrenal glands retain normal responsiveness to ACTH, suggesting that moderate decreases in daily ACTH secretion are compatible with sustaining normal adrenal function. Hence, the site of the mild suppression of the hypothalamic-pituitary-adrenal axis during chronic, alternate day treatment with glucocorticoids is central, whereas the adrenal glands appear to remain functionally unaffected.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2987294     DOI: 10.1210/jcem-61-1-22

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  7 in total

1.  [Risk of adrenal cortex insufficiency following heart transplantation].

Authors:  M Hummel; H Warnecke; S Schüler; K Luding; R Hetzer
Journal:  Klin Wochenschr       Date:  1991-04-04

2.  Impaired diurnal adrenal rhythmicity restored by constant infusion of corticotropin-releasing hormone in corticotropin-releasing hormone-deficient mice.

Authors:  L J Muglia; L Jacobson; S C Weninger; C E Luedke; D S Bae; K H Jeong; J A Majzoub
Journal:  J Clin Invest       Date:  1997-06-15       Impact factor: 14.808

3.  Corticotroph isolation from Pomc-eGFP mice reveals sustained transcriptional dysregulation characterising a mouse model of glucocorticoid-induced suppression of the hypothalamus-pituitary-adrenal axis.

Authors:  Peter J Duncan; Heather McClafferty; Oscar Nolan; Qinghui Ding; Natalie Z M Homer; Paul Le Tissier; Brian R Walker; Michael J Shipston; Nicola Romanò; Thomas J G Chambers
Journal:  J Neuroendocrinol       Date:  2022-07-14       Impact factor: 3.870

4.  Hypothalamic and suprahypothalamic effects of prolonged treatment with dexamethasone in the rat.

Authors:  A E Calogero; C Liapi; G P Chrousos
Journal:  J Endocrinol Invest       Date:  1991-04       Impact factor: 4.256

5.  Human corticotropin-releasing factor plus lysine vasopressin test during glucocorticoid therapy.

Authors:  K Hashimoto; S Suemaru; T Takao; M Sugawara; T Hattori; J Kageyama; K Takahashi; Z Ota
Journal:  J Clin Invest       Date:  1988-07       Impact factor: 14.808

6.  Treatment of moderately to severely active systemic lupus erythematosus with adrenocorticotropic hormone: a single-site, open-label trial.

Authors:  J J Fiechtner; T Montroy
Journal:  Lupus       Date:  2014-05-02       Impact factor: 2.911

7.  Systemic glucocorticoid therapy and adrenal insufficiency in adults: A systematic review.

Authors:  Rebecca M Joseph; Ann Louise Hunter; David W Ray; William G Dixon
Journal:  Semin Arthritis Rheum       Date:  2016-03-09       Impact factor: 5.532

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.